The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLC
Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses updated findings from the Phase III MARIPOSA study (NCT04487080), where first-line (1L) treatment with amivantamab plus lazertinib significantly improved progression-free survival compared to osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). Fewer patients receiving amivantamab plus lazertinib developed resistance mutations like MET amplification or EGFR alterations. These findings suggest that amivantamab plus lazertinib alters the biology of acquired resistance, particularly through EGFR and MET inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
